Tarsus joins Stargardt race to market with $800m Alkeus takeover
Tarsus Pharmaceuticals has forged a takeover deal with Alkeus Pharmaceuticals worth up to $800m, adding a Stargardt disease asset with …
Post
-
-
Context drops bispecific T-cell engager on cost-cutting initiative
Philadelphia-based biotech Context Therapeutics has terminated the development programme for one of its pipeline bispecific T-cell engagers (BiTEs) as the …
-
Moderna mRNA flu shot wins FDA approval but awaits CDC recommendations
Moderna has secured US Food and Drug Administration (FDA) approval for its mRNA influenza vaccine, overcoming initial data qualms from …
-
Evotec and Odyssey collaborate on AI-enabled R&D
Evotec and Odyssey Therapeutics have announced a strategic AI-enabled research and development (R&D) partnership to explore new treatments for autoimmune and …
-
Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases. These conditions …
-
Takeda nets first-in-class advantage on narcolepsy drug’s FDA go-ahead
The US Food and Drug Administration (FDA) has approved Takeda’s oral orexin receptor agonist, oveporexton, for a form of narcolepsy …
-
Rethinking sterile product development for manufacturing success
Where innovation excels, investment follows. Set against high growth of next-generation modalities, pharmaceutical manufacturing is entering one of its most …
-
Eli Lilly raises 2026 outlook again as Q2 soars past estimates
Eli Lilly has lifted its full-year outlook for the second time this year on the back of another strong quarter, …
-
Alteogen signs $365m Hybrozyme licensing deal with pharma company
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide …
-
China-ready by design: Leveraging NMPA’s new 30‑working day IND pathway
Over the last decade, China has become a key destination for oncology clinical trials, with Chinese sites increasingly incorporated within …
-
Schrödinger and BMS expand partnership to deploy AI for drug discovery
Schrödinger has entered a strategic agreement with Bristol Myers Squibb (BMS) to integrate its AI-based co-scientist platform Bunsen into BMS’s …
-
Why manual aseptic filling often provides faster start dates than automated lines
A Phase 1 start date may be tied to investor milestones. A rare disease therapy may represent a small patient …
-
Novo Nordisk not currently in a position to pursue large-scale M&A, CEO says
After a year at the helm, Novo Nordisk’s CEO Maziar Mike Doustdar’s task of closing the gap to pacesetter Eli …
-
What is ‘Premium Content’ on Pharmaceutical Technology?
Pharmaceutical Technology has introduced new ‘Premium Content’ for its readers – here’s an explanation of what’s changing and what isn’t. Premium …
-
Orexin receptor agonists set to propel narcolepsy treatment into a new era
Note: A few hours after this article was published, oveporexton was approved as a treatment for narcolepsy type 1. More …
